Trial reportAIDS and behavior2019
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial.
Trial report in AIDS and behavior, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01227044 (Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention), which is not on this map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review.Substance abuse treatment, prevention, and policy · 2020Pooled it
- Integrated stepped alcohol treatment for patients with HIV and at-risk alcohol use: a randomized trial.Addiction science & clinical practice · 2020Trial
- Trial
- Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial.Journal of substance abuse treatment · 2019Trial
- Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.Alcoholism, clinical and experimental research · 2019Trial
- Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial.The lancet. HIV · 2019Trial
- The Roles of Endogenous D2R Dopamine and μ-opioid Receptors of the Brain in Alcohol use Disorder.Current medicinal chemistry · 2024Review
- Contingency management with stepped care for unhealthy alcohol use among individuals with HIV: Protocol for a randomized controlled trial.Contemporary clinical trials · 2023Article
- Characterizing Unhealthy Alcohol Use Patterns and Their Association with Alcohol Use Reduction and Alcohol Use Disorder During Follow-Up in HIV Care.AIDS and behavior · 2023Article
- Patient-Reported Bothersome Symptoms Attributed to Alcohol Use Among People With and Without HIV.AIDS and behavior · 2022Article
- Practices, attitudes, and confidence related to tobacco treatment interventions in HIV clinics: a multisite cross-sectional survey.Translational behavioral medicine · 2022Article
- Treatment for alcohol use disorder among persons with and without HIV in a clinical care setting in the United States.Drug and alcohol dependence · 2021Article
- Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation.Journal of acquired immune deficiency syndromes (1999) · 2021Article
- Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.Patient preference and adherence · 2021Review
- Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis.Drug and alcohol dependence · 2020Article
- Working with HIV clinics to adopt addiction treatment using implementation facilitation (WHAT-IF?): Rationale and design for a hybrid type 3 effectiveness-implementation study.Contemporary clinical trials · 2020Article
- Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review.Current HIV/AIDS reports · 2020Review
- Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.Journal of substance abuse treatment · 2020Article
- Substance use service availability in HIV treatment programs: Data from the global IeDEA consortium, 2014-2015 and 2017.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
We sought to test the efficacy of extended-release naltrexone (XR-NTX) on HIV-related and drinking outcomes. From April 2011-February 2015, we conducted a 4-site randomized double-blind placebo controlled clinical trial involving 51 HIV-positive patients with heavy drinking and < 95% antiretroviral (ART) adherence. All participants received counseling. The primary outcome was proportion with ≥ 95% ART adherence. Secondary outcomes included HIV biomarkers, VACS Index score, and past 30-day heavy drinking days. Based on receipt of ≥ 5 injections, 23 participants were retained at 24 weeks. We did not detect an effect of XR-NTX on ART adherence (p = 0.38); undetectable HIV viral load (p = 0.26); CD4 cell count (p = 0.75) or VACS Index score (p = 0.70). XR-NTX was associated with fewer heavy drinking days (p = 0.03). While XR-NTX decreases heavy drinking days, we did not detect improvements in ART adherence or HIV outcomes. Strategies to improve retention in alcohol treatment and HIV-related outcomes among heavy drinking HIV-positive patients are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.